levodopa/carbidopa fairmed 100 mg/25 mg tabletes
fairmed healthcare gmbh, germany - levodopum, carbidopum - tablete - 100 mg/25 mg
levodopa/carbidopa fairmed 250 mg/25 mg tabletes
fairmed healthcare gmbh, germany - levodopum, carbidopum - tablete - 250 mg/25 mg
gabapentin strides 100 mg cietās kapsulas
strides pharma (cyprus) limited, cyprus - gabapentīns - kapsula, cietā - 100 mg
gabapentin strides 300 mg cietās kapsulas
strides pharma (cyprus) limited, cyprus - gabapentīns - kapsula, cietā - 300 mg
gabapentin strides 400 mg cietās kapsulas
strides pharma (cyprus) limited, cyprus - gabapentīns - kapsula, cietā - 400 mg
alfacalcidol strides pharma 0,25 mikrogrami mīkstās kapsulas
strides pharma (cyprus) limited, cyprus - alfakalcidols - kapsula, mīkstā - 0,25 µg
alfacalcidol strides pharma 0,5 mikrogrami mīkstās kapsulas
strides pharma (cyprus) limited, cyprus - alfakalcidols - kapsula, mīkstā - 0,5 µg
alfacalcidol strides pharma 1 mikrograms mīkstās kapsulas
strides pharma (cyprus) limited, cyprus - alfakalcidols - kapsula, mīkstā - 1 µg
kauliv
strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalcija homeostāze - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
plerixafor accord
accord healthcare s.l.u. - pleriksafors - multiple myeloma; hematopoietic stem cell transplantation - imunitātes stimulatori, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.